Figure 1

Effect of cardioprotective treatments on area-at-risk, myocardial infarct size in mouse AMI model. (A) Myocardial AAR as a fraction of left ventricle area (AAR/LV%) determined by ex vivo histological staining. AAR/LV%: control 64.3 ± 6.1, n = 6; IPC 59.8 ± 7.9, n = 10; vehicle 65.4 ± 7.0, n = 8; CsA 58.0 ± 12.6, n = 9; data are mean ± SD; one-way ANOVA p = 0.18. (B) Infarct size as a fraction of AAR (IS/AAR%) determined by ex vivo histological staining. IPC study: IS/AAR%: control 50.6 ± 6.9, n = 6; IPC 27.9 ± 3.7, n = 10; unpaired t-test ***p < 0.001. CsA study: vehicle 56.6 ± 13.6, n = 7; CsA 38.6 ± 7.8, n = 9; data are mean ± SD; unpaired t-test **p = 0.004. (C–H) These figures show the effects of control, IPC, vehicle and CsA on left ventricular mass, end systolic volume, ejection fraction, end diastolic volume, stroke volume and cardiac output. *p = 0.0082.